Found: 52
Select item for more details and to access through your institution.
Efficacy and safety of rechallenge [<sup>177</sup>Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2024, v. 51, n. 13, p. 4151, doi. 10.1007/s00259-024-06825-4
- By:
- Publication type:
- Article
[ 89 Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Prior Indetermined Findings on [ 18 F]PSMA-1007 Imaging.
- Published in:
- Diagnostics (2075-4418), 2024, v. 14, n. 20, p. 2321, doi. 10.3390/diagnostics14202321
- By:
- Publication type:
- Article
Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy.
- Published in:
- Cancers, 2024, v. 16, n. 20, p. 3532, doi. 10.3390/cancers16203532
- By:
- Publication type:
- Article
Efficacy and Safety of [ 225 Ac]Ac-PSMA-617 Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis.
- Published in:
- Pharmaceutics, 2021, v. 13, n. 5, p. 722, doi. 10.3390/pharmaceutics13050722
- By:
- Publication type:
- Article
Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes.
- Published in:
- Pharmaceuticals (14248247), 2024, v. 17, n. 8, p. 1080, doi. 10.3390/ph17081080
- By:
- Publication type:
- Article
Benefit of including CT urography in [<sup>68</sup>Ga]PSMA-11 PET/CT with low-dose CT: first results from a larger prostate cancer cohort analysis.
- Published in:
- Quarterly Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 66, n. 3, p. 280, doi. 10.23736/S1824-4785.20.03224-0
- By:
- Publication type:
- Article
Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of 64Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates.
- Published in:
- Molecular Imaging & Biology, 2021, v. 23, n. 1, p. 95, doi. 10.1007/s11307-020-01530-8
- By:
- Publication type:
- Article
The Influence of Hypothyroid Metabolic Status on Blood Coagulation and the Acquired von Willebrand Syndrome.
- Published in:
- Journal of Clinical Medicine, 2023, v. 12, n. 18, p. 5905, doi. 10.3390/jcm12185905
- By:
- Publication type:
- Article
Primary Staging of Prostate Cancer Patients with [ 18 F]PSMA-1007 PET/CT Compared with [ 68 Ga]Ga-PSMA-11 PET/CT.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 17, p. 5064, doi. 10.3390/jcm11175064
- By:
- Publication type:
- Article
Comparison of different methods for post-therapeutic dosimetry in [177Lu]Lu-PSMA-617 radioligand therapy.
- Published in:
- EJNMMI Physics, 2021, v. 8, n. 1, p. 1, doi. 10.1186/s40658-021-00385-4
- By:
- Publication type:
- Article
Image quality analysis of 44Sc on two preclinical PET scanners: a comparison to 68Ga.
- Published in:
- EJNMMI Physics, 2020, v. 7, n. 1, p. 1, doi. 10.1186/s40658-020-0286-3
- By:
- Publication type:
- Article
Dual FDG/PSMA PET imaging to predict lesion-based progression of mCRPC during PSMA-RLT.
- Published in:
- Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-61961-z
- By:
- Publication type:
- Article
Response Assessment and Prediction of Progression-Free Survival by 68 Ga-PSMA-11 PET/CT Based on Tumor-to-Liver Ratio (TLR) in Patients with mCRPC Undergoing 177 Lu-PSMA-617 Radioligand Therapy.
- Published in:
- Biomolecules (2218-273X), 2021, v. 11, n. 8, p. 1099, doi. 10.3390/biom11081099
- By:
- Publication type:
- Article
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival.
- Published in:
- Cancers, 2024, v. 16, n. 15, p. 2670, doi. 10.3390/cancers16152670
- By:
- Publication type:
- Article
Tumor Sink Effect with Prostate-Specific Membrane Antigen-Targeted Theranostics in Patients with Metastatic Castration-Resistant Prostate Cancer: Intra-Individual Evaluations.
- Published in:
- Cancers, 2023, v. 15, n. 9, p. 2592, doi. 10.3390/cancers15092592
- By:
- Publication type:
- Article
Detection Efficacy of 68 Ga-PSMA-11 PET/CT in Biochemical Recurrence of Prostate Cancer with Very Low PSA Levels: A 7-Year, Two-Center "Real-World" Experience.
- Published in:
- Cancers, 2023, v. 15, n. 5, p. 1376, doi. 10.3390/cancers15051376
- By:
- Publication type:
- Article
Addition of Standard Enzalutamide Medication Shows Synergistic Effects on Response to [ 177 Lu]Lu-PSMA-617 Radioligand Therapy in mCRPC Patients with Imminent Treatment Failure—Preliminary Evidence of Pilot Experience.
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2691, doi. 10.3390/cancers14112691
- By:
- Publication type:
- Article
Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC.
- Published in:
- Cancers, 2022, v. 14, n. 7, p. 1696, doi. 10.3390/cancers14071696
- By:
- Publication type:
- Article
Comparison of [ 18 F]PSMA-1007 with [ 68 Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse.
- Published in:
- Cancers, 2022, v. 14, n. 6, p. 1479, doi. 10.3390/cancers14061479
- By:
- Publication type:
- Article
Value of Combined PET Imaging with [ 18 F]FDG and [ 68 Ga]Ga-PSMA-11 in mCRPC Patients with Worsening Disease during [ 177 Lu]Lu-PSMA-617 RLT.
- Published in:
- Cancers, 2021, v. 13, n. 16, p. 4134, doi. 10.3390/cancers13164134
- By:
- Publication type:
- Article
Renal Safety of [ 177 Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Compromised Baseline Kidney Function.
- Published in:
- Cancers, 2021, v. 13, n. 12, p. 3095, doi. 10.3390/cancers13123095
- By:
- Publication type:
- Article
Dual-Time Point [ 68 Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 10, p. 2788, doi. 10.3390/cancers12102788
- By:
- Publication type:
- Article
PSA and PSA Kinetics Thresholds for the Presence of 68Ga-PSMA-11 PET/CT-Detectable Lesions in Patients with Biochemical Recurrent Prostate Cancer.
- Published in:
- Cancers, 2020, v. 12, n. 2, p. 398, doi. 10.3390/cancers12020398
- By:
- Publication type:
- Article
Neuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patients.
- Published in:
- EJNMMI Research, 2020, v. 10, n. 1, p. 1, doi. 10.1186/s13550-020-00640-2
- By:
- Publication type:
- Article
Outstanding increase in tumor-to-background ratio over time allows tumor localization by [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in early biochemical recurrence of prostate cancer.
- Published in:
- Cancer Imaging, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s40644-024-00778-5
- By:
- Publication type:
- Article
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis.
- Published in:
- Cancer Imaging, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s40644-024-00671-1
- By:
- Publication type:
- Article
Striatal dopamine transporters and cognitive function in Parkinson's disease.
- Published in:
- Acta Neurologica Scandinavica, 2020, v. 142, n. 4, p. 385, doi. 10.1111/ane.13320
- By:
- Publication type:
- Article
Cutting the Gordian Knot: Rare Presentation of Nodular Fasciitis as Supraclavicular Swelling with Muscular Involvement in 68 Ga-FAPI-PET/CT.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Histopathological Confirmed Polycythemia Vera with Transformation to Myelofibrosis Depicted on [ 18 F]FDG PET/CT.
- Published in:
- Diagnostics (2075-4418), 2024, v. 14, n. 10, p. 982, doi. 10.3390/diagnostics14100982
- By:
- Publication type:
- Article
Mind the Pitfall: Solitary Nodular Fasciitis Mimicking Extra-Nodal Manifestation of Hodgkin Lymphoma on [ 18 F]FDG PET/CT.
- Published in:
- Diagnostics (2075-4418), 2024, v. 14, n. 8, p. 783, doi. 10.3390/diagnostics14080783
- By:
- Publication type:
- Article
Active Lumbar Spondylodiscitis on [ 68 Ga]Ga-PSMA-11 PET/CT Mimicking Bone Metastasis.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Histologically Confirmed Testicular Metastasis Revealed by [ 89 Zr]Zr-PSMA-617 PET/CT in a Patient with Biochemical Recurrence of Prostate Cancer and Negative Conventional PSMA PET/CT Imaging.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Strongly Radioiodine-Positive Pancreatic Adenocarcinoma Mimicking Metastasis of Differentiated Thyroid Cancer.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [ 68 Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 5, p. N.PAG, doi. 10.3390/diagnostics12051211
- By:
- Publication type:
- Article
Systemic Mastocytosis Treatment with Midostaurin: [ 18 F]FDG PET/CT as a Potential Monitoring Tool for Therapy Outcome.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 3, p. 680, doi. 10.3390/diagnostics12030680
- By:
- Publication type:
- Article
Unusual Case of Splenic Metastasis in Adenosquamous Carcinoma of the Cervix Uteri: Diagnosis and Treatment Considerations.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Concomitant lithium increases radioiodine uptake and absorbed doses per administered activity in graves' disease: comparison of conventional versus lithium-augmented radioiodine therapy.
- Published in:
- Frontiers in Medicine, 2024, p. 1, doi. 10.3389/fmed.2024.1382024
- By:
- Publication type:
- Article
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.
- Published in:
- Frontiers in Medicine, 2024, p. 1, doi. 10.3389/fmed.2023.1339160
- By:
- Publication type:
- Article
Change of glucometabolic activity per PSMA expression predicts survival in mCRPC patients non-responding to PSMA radioligand therapy: introducing a novel dual imaging biomarker.
- Published in:
- Frontiers in Medicine, 2024, p. 1, doi. 10.3389/fmed.2023.1339160
- By:
- Publication type:
- Article
[<sup>161</sup>Tb]Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [<sup>177</sup>Lu]Lu-PSMA-617.
- Published in:
- Theranostics, 2024, v. 14, n. 5, p. 1829, doi. 10.7150/thno.92273
- By:
- Publication type:
- Article
Molecular imaging and biochemical response assessment after a single cycle of [<sup>225</sup>Ac]Ac-PSMA-617/[<sup>177</sup>Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [<sup>177</sup>Lu]Lu-PSMA-617 monotherapy.
- Published in:
- Theranostics, 2021, v. 11, n. 9, p. 4050, doi. 10.7150/thno.56211
- By:
- Publication type:
- Article
18F-FDG PET/CT: an unexpected case of Huntington's disease.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Change in total lesion PSMA (TLP) during [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2024, v. 51, n. 3, p. 885, doi. 10.1007/s00259-023-06476-x
- By:
- Publication type:
- Article
Detection efficacy of [<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2023, v. 50, n. 9, p. 2899, doi. 10.1007/s00259-023-06241-0
- By:
- Publication type:
- Article
[<sup>89</sup>Zr]Zr-PSMA-617 PET/CT in biochemical recurrence of prostate cancer: first clinical experience from a pilot study including biodistribution and dose estimates.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 13, p. 4736, doi. 10.1007/s00259-022-05925-3
- By:
- Publication type:
- Article
<sup>89</sup>Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 6, p. 2064, doi. 10.1007/s00259-021-05661-0
- By:
- Publication type:
- Article
Early molecular imaging response assessment based on determination of total viable tumor burden in [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [<sup>177</sup>Lu]Lu-PSMA-617 radioligand therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 5, p. 1584, doi. 10.1007/s00259-021-05594-8
- By:
- Publication type:
- Article
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2022, v. 49, n. 3, p. 1075, doi. 10.1007/s00259-021-05525-7
- By:
- Publication type:
- Article
Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 1, p. 103, doi. 10.1007/s00259-020-04828-5
- By:
- Publication type:
- Article
Positive FAPI-PET/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative/FDG-positive disease.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2020, v. 47, n. 8, p. 2040, doi. 10.1007/s00259-019-04623-x
- By:
- Publication type:
- Article